N-(4-bromophenyl)-N-phenyl-[1,1’-biphenyl]-4-amine

We are N-(4-bromophenyl)-N-phenyl-[1,1’-biphenyl]-4-amine CAS:503299-24-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-(4-bromophenyl)-N-phenyl-[1,1’-biphenyl]-4-amine
CAS.NO:503299-24-9
Synonyms:4-bromo-4'-phenyltriphenylamine
(4-bromo-phenyl)-(biphenyl-4-yl)-phenyl-amine
N-(4-bromophenyl)-N-phenyl-[1,1'-Biphenyl]-4-amine
Molecular Formula:C24H18BrN
Molecular Weight:400.31000
 
Specification:
Appearance:White powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

N-(4-bromophenyl)-N-phenyl-[1,1’-biphenyl]-4-amine


Related News: From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.Acetato de [(2S) -1-acetamido-3-cloropropan-2-il] CAS:183905-31-9 We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.2-Ethyl-3-methylpyrazine This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?3-Bromo-6-chloro-2-fluoropyridine ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses.In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.

Related Products
Product Name
(2S,3aS,7aS)-Octahydroindole-2-carboxylic acid View Details
1-oxido-2-[(1,3,4-trimethyl-4,5-dihydroimidazol-1-ium-2-yl)sulfanyl]pyridin-1-ium,hexafluorophosphate View Details
p-Anisaldehyde View Details
1-(4-phenyl-1H-imidazol-2-yl)-ethylamine manufacturer 2-bromo-1-(3,5-difluorophenyl)ethanone manufacturer 2,5-Dimethoxyphenylboronic acid manufacturer 2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid manufacturer 2,4-Difluorobenzyl Alcohol manufacturer